BCL2 rs12457371: What Your Genotype Means
The rs12457371 variant is a single nucleotide polymorphism located within the BCL2 gene, which plays a critical role in regulating programmed cell death. Research has identified this variant as having a moderate association with the development of chronic lymphocytic leukemia (CLL) and the regulation of immune cell subsets.
What each genotype means
Baseline BCL2 variant profile
This genotype represents the homozygous state for the A allele at this position in the BCL2 gene. Research indicates that this variant is associated with susceptibility to chronic lymphocytic leukemia and may influence immune cell subset regulation, though it is not a diagnostic marker for disease. You should discuss any concerns regarding your personal health history or immune function with your healthcare provider.
The frequency of this genotype varies significantly across different global populations and ancestral backgrounds.
Baseline BCL2 variant profile
This genotype represents the heterozygous state for the A and G alleles at this position in the BCL2 gene. Research indicates that this variant is associated with susceptibility to chronic lymphocytic leukemia and may influence immune cell subset regulation, though it is not a diagnostic marker for disease. You should discuss any concerns regarding your personal health history or immune function with your healthcare provider.
The frequency of this genotype varies significantly across different global populations and ancestral backgrounds.
Baseline BCL2 variant profile
This genotype represents the homozygous state for the G allele at this position in the BCL2 gene. Research indicates that this variant is associated with susceptibility to chronic lymphocytic leukemia and may influence immune cell subset regulation, though it is not a diagnostic marker for disease. You should discuss any concerns regarding your personal health history or immune function with your healthcare provider.
The frequency of this genotype varies significantly across different global populations and ancestral backgrounds.
Understanding the rs12457371 Variant
A single nucleotide polymorphism, or SNP, is a variation at a single position in a DNA sequence among individuals. The rs12457371 variant is located within the BCL2 gene, which is situated on chromosome 18. In the context of genomics, SNPs like rs12457371 serve as markers that researchers use to study how specific genetic differences might influence biological traits or disease susceptibility. Because this variant is located in a region associated with immune function, scientists have focused on how it might alter the expression or regulation of the BCL2 protein, which is essential for maintaining the balance of cell survival and death in the body.
The Role of the BCL2 Gene
The BCL2 gene provides instructions for making the Bcl-2 protein, a key regulator of apoptosis, or programmed cell death. Apoptosis is a vital process that allows the body to eliminate old, damaged, or unnecessary cells. When the BCL2 gene functions correctly, it helps ensure that immune cells, such as B-cells, survive only as long as they are needed. However, if the BCL2 gene is dysregulated—often through chromosomal translocations or other genetic variations—it can lead to the overproduction of the Bcl-2 protein. This prevents cells from undergoing apoptosis when they should, potentially allowing abnormal cells to accumulate. This mechanism is a well-documented factor in the development of certain lymphoid malignancies, including chronic lymphocytic leukemia.
Research and Evidence Strength
The association between rs12457371 and chronic lymphocytic leukemia (CLL) is categorized as having moderate evidence strength. Genome-wide association studies (GWAS) have identified this SNP as a potential susceptibility locus, meaning individuals carrying specific alleles may show a statistically different risk profile compared to the general population. It is important to note that genetic association does not imply causation; having a particular genotype does not mean an individual will develop a disease. The biological impact of this SNP is likely influenced by complex interactions with other genes and environmental factors. Current research continues to investigate how this variant specifically impacts immune cell subset regulation, but the evidence remains an area of active study rather than a definitive clinical diagnostic tool.
Population Frequency and Variability
The frequency of the rs12457371 variant is known to be variable across different global populations. Genetic databases indicate that the distribution of the alleles for this SNP is not uniform, with significant differences observed between various ancestral groups. This variability is common in human genetics, as evolutionary pressures and population history shape the prevalence of specific variants over time. Because the frequency is variable, the potential impact of this SNP on disease risk may also differ depending on an individual's genetic background. Researchers use this population-level data to better understand the architecture of complex diseases and to ensure that genetic studies are representative of diverse human populations.
What This Information Means for You
Information regarding the rs12457371 variant is intended for educational purposes and should not be used for medical diagnosis or personal health decision-making. Genetic variants are only one piece of a much larger puzzle that includes lifestyle, environment, and other genetic factors. If you are concerned about your risk for leukemia or other immune-related conditions, it is essential to consult with a qualified healthcare professional or a genetic counselor. They can provide context based on your personal and family medical history. Furthermore, if you are currently undergoing treatment for a condition involving BCL2-related pathways, always discuss any questions regarding medications or clinical management with your clinician or pharmacist, as they are best equipped to guide your care.
How common is this variant?
The frequency of the rs12457371 variant is variable across different global populations, with no single allele being universally dominant across all ancestral groups.
Frequently asked questions
Is rs12457371 a diagnostic test for leukemia?
No, rs12457371 is not a diagnostic test. It is a genetic variant associated with a statistical change in risk, not a definitive indicator of disease presence or future development.
Can I change my risk associated with BCL2 variants?
Genetic variants are inherited and cannot be changed. However, maintaining a healthy lifestyle and regular medical screenings are the most effective ways to manage overall health and monitor for potential issues.
What should I do if I have a high-risk genotype?
If you are concerned about your genetic results, you should speak with a healthcare provider or a genetic counselor. They can help interpret your results in the context of your overall health and family history.
Does this variant affect how BCL2 inhibitors work?
While BCL2 inhibitors like venetoclax target the BCL2 protein, there is no current clinical consensus that the rs12457371 variant dictates treatment response. Always consult your oncologist regarding specific medication efficacy.
Sources & further reading
Educational information only, last refreshed 10/10/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs12457371?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in BCL2
A newly identified autophagy-related variant linked to chronic lymphocytic leukemia risk and altered cytokine production.
An autophagy-related genetic variant identified as a risk factor for chronic lymphocytic leukemia.
This BCL2 variant is associated with survival outcomes in patients treated with R-CHOP for lymphoma, specifically showing treatment-dependent risk modulation.
This BCL2 intronic variant shows significant interaction with R-CHOP treatment efficacy in patients with diffuse large B-cell lymphoma.